CINETTO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.477
AS - Asia 5.653
EU - Europa 3.185
SA - Sud America 920
AF - Africa 880
Continente sconosciuto - Info sul continente non disponibili 245
OC - Oceania 84
Totale 19.444
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.897
SG - Singapore 1.661
IT - Italia 1.061
VN - Vietnam 989
CN - Cina 935
HK - Hong Kong 579
BR - Brasile 540
DE - Germania 301
FI - Finlandia 221
BD - Bangladesh 208
IN - India 190
GB - Regno Unito 185
FR - Francia 169
PL - Polonia 149
NL - Olanda 141
CA - Canada 117
IQ - Iraq 105
SE - Svezia 97
TR - Turchia 92
AR - Argentina 90
RU - Federazione Russa 90
JP - Giappone 83
UA - Ucraina 72
MX - Messico 70
PH - Filippine 64
PK - Pakistan 61
ES - Italia 58
EC - Ecuador 52
ID - Indonesia 52
ZA - Sudafrica 52
AT - Austria 47
KR - Corea 44
MY - Malesia 43
CO - Colombia 42
SA - Arabia Saudita 42
IE - Irlanda 41
UZ - Uzbekistan 41
VE - Venezuela 41
CR - Costa Rica 37
BJ - Benin 35
ET - Etiopia 35
TN - Tunisia 32
KE - Kenya 31
PE - Perù 31
PY - Paraguay 30
UY - Uruguay 30
JM - Giamaica 29
LC - Santa Lucia 29
RO - Romania 29
AU - Australia 28
DK - Danimarca 28
MA - Marocco 28
NG - Nigeria 28
RS - Serbia 28
AE - Emirati Arabi Uniti 27
EG - Egitto 27
AZ - Azerbaigian 26
BY - Bielorussia 26
HN - Honduras 26
KZ - Kazakistan 26
ME - Montenegro 26
NP - Nepal 26
BZ - Belize 25
CI - Costa d'Avorio 25
CL - Cile 25
CZ - Repubblica Ceca 25
EE - Estonia 25
MG - Madagascar 25
SK - Slovacchia (Repubblica Slovacca) 25
TZ - Tanzania 25
BE - Belgio 24
CH - Svizzera 24
GR - Grecia 24
IS - Islanda 24
TJ - Tagikistan 24
ZW - Zimbabwe 24
CV - Capo Verde 23
LB - Libano 23
MD - Moldavia 23
AM - Armenia 22
CG - Congo 22
CY - Cipro 22
DZ - Algeria 22
GH - Ghana 22
GT - Guatemala 22
LV - Lettonia 22
MK - Macedonia 22
MR - Mauritania 22
MU - Mauritius 22
NI - Nicaragua 22
PA - Panama 22
PT - Portogallo 22
RW - Ruanda 22
SN - Senegal 22
AL - Albania 21
CD - Congo 21
CW - ???statistics.table.value.countryCode.CW??? 21
JO - Giordania 21
PR - Porto Rico 21
PS - Palestinian Territory 21
Totale 18.289
Salva come PNG Salva come JPEG
Città #
Ashburn 1.201
Singapore 1.016
San Jose 898
Fairfield 689
Hong Kong 506
Woodbridge 386
Chandler 345
Ho Chi Minh City 312
Houston 301
Seattle 263
Cambridge 248
Hanoi 233
Santa Clara 226
Los Angeles 203
Beijing 189
Wilmington 189
Ann Arbor 177
Helsinki 136
New York 135
Council Bluffs 131
Boardman 117
Munich 110
Milan 105
Bytom 100
San Diego 99
Padova 95
Da Nang 81
Lauterbourg 78
Princeton 74
Medford 65
Rome 63
Des Moines 60
Tokyo 60
Dallas 59
Guangzhou 49
Orem 49
London 47
São Paulo 47
Hefei 46
Baghdad 44
Chicago 39
Chennai 38
Haiphong 37
Buffalo 36
Cotonou 35
Tashkent 35
Montreal 34
Phoenix 33
Warsaw 32
Dublin 30
Addis Ababa 28
Lappeenranta 28
Nairobi 28
Seoul 28
Castries 27
Nanjing 27
Turku 27
Denver 26
Frankfurt am Main 26
Istanbul 26
Montevideo 25
Padua 25
Roxbury 25
Vienna 25
Abidjan 24
Atlanta 24
Bologna 24
Lima 24
Biên Hòa 23
Poplar 23
Rio de Janeiro 23
San Francisco 23
San José 23
Toronto 23
Ankara 22
Baku 22
Kigali 22
Panama City 22
Podgorica 22
The Dalles 22
Amsterdam 21
Antananarivo 21
Dakar 21
Dushanbe 21
Harare 21
Riga 21
Turin 21
Amman 20
Johannesburg 20
Managua 20
Nouakchott 20
Bridgetown 19
Dar es Salaam 19
Hải Dương 19
Kingstown 19
Kinshasa 19
Lahore 19
Libreville 19
Naples 19
Nuremberg 19
Totale 10.716
Salva come PNG Salva come JPEG
Nome #
Granulomatous Lymphocytic Interstitial Lung Disease (GLILD) in Common Variable Immunodeficiency (CVID): A Multicenter Retrospective Study of Patients From Italian PID Referral Centers 369
Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies 367
L-Arginine prevents inflammatory and pro-calcific differentiation of interstitial aortic valve cells 364
Glycogen synthase kinase-3 (GSK-3) in the pathogenesis of pulmonary fibrosis: what we know from the mouse model 357
The emerging role of nutraceuticals in cardiovascular calcification: Evidence from preclinical and clinical studies 356
3-(2,4-Dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763), a Glycogen Synthase Kinase-3 Inhibitor, Displays Therapeutic Properties in a Mouse Model of Pulmonary Inflammation and Fibrosis 322
No differences in nasal tissue inflammatory cells and adhesion molecules (iCAM-1 and vCAM-1) comparing EGPA with eosinophilic chronic sinusitis with polyposis. 303
Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study 293
Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients. 281
Warfarin, but not rivaroxaban, promotes the calcification of the aortic valve in ApoE−/− mice 279
Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: results from an Italian cohort of 133 hypertensives 270
Overall Disability Sum Score for Clinical Assessment of Neurological Involvement in Eosinophilic Granulomatosis with Polyangiitis 266
Venom immunotherapy during COVID-19 pandemic: Experience from a University Allergy Center in Northern Italy 265
Gastric cancer is the leading cause of death in Italian adult patients with common variable immunodeficiency 254
The immunopathogenesis of sarcoidosis 248
Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study 246
A new cytological approach to improve the final diagnosis of Eosinophilic Granulomatosis with Polyangiitis (EGPA) 245
Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis 242
Predictors of Splenectomy Response in Immune Thrombocytopenia: A Multicentric Italian Study 237
Immunology of sarcoidosis: old companions, new relationships 236
Serum uric acid levels and the risk of recurrent venous thromboembolism 235
Serum Free Light Chains in Common Variable Immunodeficiency Disorders: Role in Differential Diagnosis and Association With Clinical Phenotype 230
A bone-based 3D scaffold as an in-vitro model of microenvironment–DLBCL lymphoma cell interaction 229
Rituximab in refractory sarcoidosis: a single centre experience 228
Severe infections unrelated to neutropenia impact on overall survival in multiple myeloma patients: results of a single centre cohort study 228
Appropriate lung management in patients with primary antibody deficiencies 226
Azathioprine in isolated recurrent pericarditis: A single centre experience 226
Serum uric acid levels and the risk of recurrent venous thromboembolism 226
Surgical Management of Hemorrhoidal Disease in Inflammatory Bowel Disease: A Systematic Review with Proportional Meta‐Analysis 226
A beacon in the dark: COVID-19 course in CVID patients from two European countries: Different approaches, similar outcomes 225
Biomarkers of Neutrophil Activation in Patients with Symptomatic Chronic Peripheral Artery Disease Predict Worse Cardiovascular Outcome 223
TL1A/DR3 axis involvement in the inflammatory cytokine network during pulmonary sarcoidosis 222
The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone 222
Comparison between dexamethasone and methylprednisolone therapy in patients with COVID-19 pneumonia admitted to non-intensive medical units 221
COVID-Q: validation of the first COVID-19 questionnaire based on patient-rated symptom gravity 220
Clinical outcome, incidence and SARS-CoV-2 infection fatality rates in Italian patients with Inborn Errors of Immunity 218
A possible role for B cells in COVID-19?: Lesson from patients with Agammaglobulinemia 214
Immunoglobulin replacement therapy in secondary hypogammaglobulinemia. 212
Advances in understanding the immunopathology of sarcoidosis and implications on therapy 211
The broad spectrum of lung diseases in primary antibody deficiencies 209
Self-administration of augmentation therapy for alpha 1-antitrypsin deficiency 208
Serum free light chains in the differential diagnosis and prognosis of primary and secondary hypogammaglobulinemia: To the editor 206
Shaping Rare Granulomatous Diseases in the Lab: How New Models Are Changing the Game 203
Are neutrophil-, eosinophil-, and basophil-to-lymphocyte ratios useful markers for pinpointing patients at higher risk of recurrent sinonasal polyps? 201
Long-term follow-up of 168 patients with X-linked agammaglobulinemia reveals increased morbidity and mortality 198
Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy 195
Vaccination in pads 195
NETosis in Acute Thrombotic Disorders 194
COVID-Q: Validation of the first COVID-19 questionnaire based on patient-rated symptom gravity 192
Sinonasal polyposis in the elderly. 186
Common variable immunodeficiency (CVID) and T immunoregulatory cells 180
Real-life data on monoclonal antibodies and antiviral drugs in Italian inborn errors of immunity patients during COVID-19 pandemic 177
Glycogen Synthase Kinase-3 inhibition with the small molecule ATP-competitive inhibitor SB216763 [3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione] prevents bleomycyn-induced lung inflammation and fibrosis. 176
Impact of Hypogammaglobulinemia on the Course of COVID-19 in a Non-Intensive Care Setting: A Single-Center Retrospective Cohort Study 176
The Effect of Isotonic Saline Nasal Lavages in Improving Symptoms in SARS-CoV-2 Infection: A Case-Control Study 175
Hyper IgE in the Allergy Clinic- when is it Primary Immunodeficiency? 173
Subcutaneous ig replacement therapy in primary and secondary hypogammaglobulinemia: A retrospective single centre study of 203 patients 172
Health-Related Quality of Life in Common Variable Immunodeficiency Italian Patients Switched to Remote Assistance During the COVID-19 Pandemic 172
The Impact of SARS-CoV-2 Infection in Patients with Inborn Errors of Immunity: the Experience of the Italian Primary Immunodeficiencies Network (IPINet) 168
Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study 166
Decline of gastric cancer mortality in common variable immunodeficiency in the years 2018-2022 165
Sarcoidosis versus Granulomatous and Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency: A Comparative Review 165
The Importance of Endoscopy with Biopsy: Real-World Evidence of Gastrointestinal Involvement in Primary Immunodeficiency in Two Main Northern Italian Centres 161
COVID-19 Clinical Features and Outcome in Italian Patients Treated with Biological Drugs Targeting Type 2 Inflammation 161
Usefulness of methotrexate in relapsing idiopathic retroperitoneal fibrosis 160
Blood eosinophil-to-basophil ratio in patients with sinonasal polyps: does it have a clinical role? 158
Double-Blind, Placebo-Controlled Randomized Trial on Low Dose Azithromycin Prophilaxis in Primary Antibody Deficiencies 156
Malignancies are the major cause of death in patients with adult onset common variable immunodeficiency. 155
Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies 155
Health-Related Quality of Life in Patients with CVID Under Different Schedules of Immunoglobulin Administration: Prospective Multicenter Study 153
Mortality in Severe Antibody Deficiencies Patients during the First Two Years of the COVID-19 Pandemic: Vaccination and Monoclonal Antibodies Efficacy 152
Editorial comment on “Expected impact of immunomodulatory agents during pregnancy: A newborn's perspective” 150
Common Clinical and Molecular Pathways between Migraine and Sarcoidosis 149
The dilemma of X-linked agammaglobulinemia carriers 149
COMMON VARIABLE IMMUNODEFICIENCY (CVID) AND T IMMUNOREGULATORY CELLS 149
Antibodies against integrin αvβ6 have high diagnostic accuracy for ulcerative colitis 148
Serum free light chains as a possible diagnostic tool in primary hypogammaglobulinemia: a multicentric study on 344 CVID patients 147
Comorbidities of sarcoidosis 144
Sarcoidosis and COVID-19: At the Cross-Road between Immunopathology and Clinical Manifestation 142
RP-HPLC-ESI-IT Mass Spectrometry Reveals Significant Variations of the Human Salivary Protein Profile Associated with Predominantly Antibody Deficiencies 142
GSK-3 Inhibition Modulates Metalloproteases in a Model of Lung Inflammation and Fibrosis 137
Chronic Kidney Disease in Common Variable Immunodeficiency: a Multicenter Study 134
TLR7 Gln11Leu single nucleotide polymorphism in patients with sarcoidosis. 131
IGA Antibody Induced by Immunization With Pneumococcal Polysaccharides Is a Prognostic Tool in Common Variable Immune Deficiencies 129
Common and Uncommon CT Findings in CVID-Related GL-ILD: Correlations with Clinical Parameters, Therapeutic Decisions and Potential Implications in the Differential Diagnosis 129
Breaking barriers: holistic assessment of ability to work in patients with sarcoidosis 124
The biological basis for current treatment strategies for granulomatous disease in common variable immunodeficiency 121
Olfactory Function Is Impaired in Patients with Mastocytosis 116
Pirfenidone treatment in a patient with IPF and possible initial hypersensitivity pulmonitis 113
Struggling with COVID-19 in Adult Inborn Errors of Immunity Patients: A Case Series of Combination Therapy and Multiple Lines of Therapy for Selected Patients 112
High Prevalence of Long COVID in Common Variable Immunodeficiency: An Italian Multicentric Study 110
Use of immunoglobulin replacement therapy in patients with secondary antibody deficiency in daily practice: a European expert Q&A-based review 109
The usefulness of scintigraphic studies in the assessment of asymptomatic bowel disease in patients with primary antibody diseases 108
Safety of mRNA COVID-19 Vaccines in Patients with Inborn Errors of Immunity: an Italian Multicentric Study 106
SARS-CoV-2 monoclonal antibody combination therapy in patients with COVID-19 and primary antibody deficiency 100
Lung function trajectories in common variable immunodeficiencies: An observational retrospective multicenter study 96
An update on appropriate lung management in patients with primary antibody deficiencies 85
Non-infectious pulmonary and gastrointestinal manifestations in primary antibody deficiencies: lessons for the clinic 78
Mepolizumab versus benralizumab for eosinophilic granulomatosis with polyangiitis (EGPA): A European real-life retrospective comparative study 65
Multidisciplinary strategies and new technologies in the management of sarcoidosis 60
Totale 19.188
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.972
article - articoli 53.623
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 108.595
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.101 0 89 206 54 66 75 57 123 71 25 135 200
2022/2023749 126 86 23 87 113 82 21 63 74 17 45 12
2023/2024568 24 53 59 51 28 85 30 39 36 39 58 66
2024/20252.533 15 121 110 104 273 96 127 239 206 112 404 726
2025/202611.101 544 779 1.317 1.530 898 544 1.853 922 1.054 666 547 447
2026/2027972 675 297 0 0 0 0 0 0 0 0 0 0
Totale 19.444